ESR1 and breast cancer: However, only 2/3 of the patients diagnosed with breast cancer express ER at diagnosis (ER+), while the other 1/3 of the cases do not express the receptors (ER-), and which is associated with non-differentiated tumors, with high cell proliferation index, poor response to endocrine therapy and poor prognosis [2].